Partnerships & Alliances
Filter News
Found 55,867 articles
-
Angle PLC Announces New Commercial Agreement with AstraZeneca
4/24/2024
ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response assay for the detection of micronuclei in CTCs as a measure of DDR.
-
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
4/24/2024
Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate 'BH3120' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors
-
Clarapath Forms Strategic Collaboration with Mayo Clinic to Advance Pathology Tissue Processing
4/23/2024
Clarapath, a medical robotics company transforming the way pathology laboratories process tissue, announced it has entered into a strategic collaboration with Mayo Clinic to propel a new era of laboratory automation.
-
Multiply Labs Announces Upcoming Collaboration with Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM) to Deploy Automated Systems For Cell Therapy Manufacturing
4/23/2024
Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced its upcoming collaboration with Stanford Medicine’s Laboratory for Cell & Gene Medicine (LCGM) to demonstrate the potential of automation technology for cell therapy manufacturing.
-
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
4/23/2024
Palisade Bio, Inc. today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.
-
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
4/23/2024
GeneDx, a leader in delivering improved health outcomes through genomic insights, announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
-
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes
4/23/2024
Vertex Pharmaceuticals Incorporated and TreeFrog Therapeutics announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes.
-
Alveo Technologies Partners with NYtor to Develop Rapid Molecular Test for the Dominant Swine Flu Strains
4/23/2024
Alveo Technologies, Inc. announced a partnership with NYtor B.V, an innovative assay developer, to create a rapid, accurate, pen-side test that will detect the dominant swine flu strains, including H1N1, H1N2 and H3N2.
-
Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging
4/23/2024
Rubedo Life Sciences announced a multi-year strategic partnership with German multinational beauty company Beiersdorf AG to develop innovative skin care products that address the effects of cellular aging.
-
Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test
4/23/2024
University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test.
-
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
4/23/2024
Lisata Therapeutics, Inc. announced that the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1 (also known as “CEND-1”), Lisata’s lead product candidate, in combination with standard-of-care (“SoC”) chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (“mPDAC”).
-
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
4/23/2024
Tharimmune, Inc. announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
-
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
-
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
-
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
4/22/2024
Bristol Myers Squibb and Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.
-
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
4/22/2024
NeuroSense Therapeutics Ltd. announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology.
-
Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease
4/22/2024
Ochre Bio, a pioneer in chronic liver disease medicine development, today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases (CLDs), such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
-
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
4/22/2024
Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Sumitomo Mitsui Banking Corporation announced that the three companies signed a master agreement on April 22, 2024, to establish a joint venture company.
-
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
4/22/2024
FSD Pharma Inc provides an update by way of a news release issued by Celly Nutrition Corp. and its launching of unbuzzd, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.
-
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
4/22/2024
Moderna, Inc. (NASDAQ:MRNA) today announced a contract with the Ministry of Health in Brazil to supply its mRNA COVID-19 vaccine as an integral part of Brazil's 2024 national vaccination campaign against COVID-19.